Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

8.67
-1.1200-11.44%
Post-market: 8.670.00000.00%18:50 EDT
Volume:939.87K
Turnover:8.20M
Market Cap:471.82M
PE:-3.81
High:9.15
Open:8.72
Low:8.10
Close:9.79
52wk High:33.68
52wk Low:5.14
Shares:54.42M
Float Shares:31.42M
Volume Ratio:0.77
T/O Rate:2.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2740
EPS(LYR):-5.5835
ROE:-35.43%
ROA:-23.99%
PB:1.39
PE(LYR):-1.55

Loading ...

Upstream Bio Cut to In-Line From Outperform by Evercore ISI Group

Dow Jones
·
Mar 27

Top Premarket Decliners

MT Newswires Live
·
Mar 27

Evercore ISI Downgrades Upstream Bio to In Line From Outperform, Adjusts PT to $15 From $40

MT Newswires Live
·
Mar 27

Upstream Bio Launches $150 Million At-The-Market Program

TIPRANKS
·
Mar 27

Upstream Bio announces $150 million at-the-market equity distribution agreement with Leerink Partners

Reuters
·
Mar 27

Upstream Bio Inc - Enters Sales Agreement With Leerink Partners Llc for Common Stock Offering of up to $150 Mln - SEC Filing

THOMSON REUTERS
·
Mar 27

Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors

TIPRANKS
·
Mar 27

Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster

TIPRANKS
·
Mar 27

Buy Rating Backed by VALIANT Phase 2 Asthma Data and Differentiated, Infrequent-Dosing Profile for Verekitug

TIPRANKS
·
Mar 26

Upstream Bio Q4 net loss widens on higher R&D costs

Reuters
·
Mar 26

Upstream Bio FY2025 net loss widens 128.4% to $143 million; research and development expenses rise 117.3% to $137 million

Reuters
·
Mar 26

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Mar 26

Upstream Bio - to Initiate Dosing in Phase 3 Trials in Both Severe Asthma and Crswnp in Q1 2027

THOMSON REUTERS
·
Mar 26

Upstream Bio Inc Q4 Net Income USD -42.459 Million

THOMSON REUTERS
·
Mar 26

Upstream Bio Inc Q4 Collaboration Revenue USD 668 Thousand

THOMSON REUTERS
·
Mar 26

Upstream Bio Inc Q4 Operating Expenses USD 46.835 Million

THOMSON REUTERS
·
Mar 26

Upstream Bio Inc expected to post a loss of 70 cents a share - Earnings Preview

Reuters
·
Mar 20

Upstream Bio CEO Makes Notable Move With Fresh Stock Sale

TIPRANKS
·
Mar 18

Buy Rating on UPB Driven by Robust Verekitug Phase 2 Data and Upcoming Phase 3 Catalysts in CRSwNP and Severe Asthma

TIPRANKS
·
Mar 03

Upstream Bio announces verekitug met the primary endpoint

TIPRANKS
·
Mar 02